Diabetes-industry veteran Fludzinski named CEO of AmideBio

BOULDER — Pawel Fludzinski has been named chief executive of AmideBio LLC, a privately held biopharmaceutical company based in Boulder.

Fludzinski, who had been acting as a senior business advisor for the firm, has an extensive background developing drugs targeting diabetes at Eli Lilly & Co.

Misha Plam, who has served as CEO since the company’s inception, will continue as president and chairman of the board of directors.

Fludzinski said AmideBio’s novel approach to developing glucose-responsive insulins “promises to radically improve diabetes treatment.”

AmideBio has a pipeline of drug candidates targeting metabolic diseases. “AmideBio…